Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (13959)	7/4/2000 6:16:05 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

And quit avoiding my 100k question Cacaito and Bluegreen.. On a further hemo trauma trial, dont forget my contention/theory that the endpoint was impossible because there was perhaps NO PLACEBO GROUP. Yes, it is possible that there was NO placebo group. So try to show a variance in that! I brought my theory to the companies attention and all they could say at the timewas they didnt think that was the case. They did not say my idea a definate wrong or impossible. According to my view>, the plaecbo group did get bpi as hard as that is to believe. And yes the company WILL acknowledge that bpi did NOT fail in hemo trauma due to a lack of drug activity. >can you imagine a drug study comparing a drug and a placebo group where the placebo group also got the drug inadvertantly by study design? Is it true? Its my theory. Do I think its true, god I hope its not true. As far as meningo goes, I guess the problem there is also not the drug but the speed to administer,the high standard of care, and difficulty in numbers. I also guess that the so called "benefit" will be fairly obvious to most all except the fda. Standard disclaimers bigtime. All my theory and guesswork. No facts.